Aliskiren

Generic Name: Aliskiren

Brand Names: Rasilez, Tekturna, Tekturna Hct

Drug Type: Small Molecule

Chemical Formula: C_₃₀H_₅₃N_₃O_₆

CAS Number: 173334-57-1

Unique Ingredient Identifier: 502FWN4Q32

Background: Aliskiren is the first drug in the renin inhibitor drug class and is used for the treatment of hypertension. It was developed by Speedel and Novartis and initially approved by the FDA in early 2007. Aliskiren has been proven to efficacious in reducing blood pressure when used alone or in conjunction with other antihypertensive agents.

Indication: Aliskiren is used for the treatment of hypertension in children above 6 years and adults. This drug may also be used in conjunction with antihypertensives such as calcium channel blockers and thiazides in products form to provide additional blood pressure control.

Associated Conditions: Hypertension

Associated Therapies: -

Clinical Trials

The Effect of Aliskiren and Losartan on Peritoneal Membrane in Continuous Ambulatory Peritoneal Dialysis Patients

Phase 4

Conditions: Peritoneal Membrane Failure

Interventions: Drug: Aliskiren plus Losartan
Drug: Enalapril plus Losartan
Drug: placebo
Drug: Aliskiren

First Posted Date: 2011-03-01

Last Posted Date: 2011-03-10

Lead Sponsor: Chulalongkorn University

Target Recruit Count: 100

Registration Number: NCT01305850

Locations: 🇹🇭
Chulalongkorn University, Bangkok, Thailand

To Study the Effects of Aliskiren on Albuminuria and Various Biomarkers in Patients With Nephropathy

Phase 2

Terminated

Conditions: Non-diabetic Nephropathy

Interventions: Drug: Aliskiren
Drug: Placebo to Aliskiren
Drug: Hydrochlorothiazide (HCTZ)
Drug: Placebo to Hydrochlorothiazide (HCTZ)
Drug: Ramipril

First Posted Date: 2011-02-24

Last Posted Date: 2013-01-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 8

Registration Number: NCT01302899

Locations: 🇳🇱
Novartis Investigative Site, Leeuwarden, Netherlands

Significance of Regional Ventriculo-arterial Coupling in Patients With Chronic Heart Failure

Not Applicable

Conditions: Heart Failure

Interventions: Drug: Aliskiren

First Posted Date: 2011-02-17

Last Posted Date: 2011-02-17

Lead Sponsor: Taipei Veterans General Hospital, Taiwan

Target Recruit Count: 120

Registration Number: NCT01298258

Locations: 🇨🇳
Taipei Veterans General Hospital, Taipei, Taiwan

Effects of Aliskiren in Elderly Hypertensive Chronic Kidney Disease (CKD) Patients

Phase 4

Completed

Conditions: Hypertension
Chronic Kidney Disease

Interventions: Drug: Aliskiren

First Posted Date: 2011-01-26

Last Posted Date: 2012-10-22

Lead Sponsor: Jichi Medical University

Target Recruit Count: 23

Registration Number: NCT01284114

Locations: 🇯🇵
Kurosu Hospital, Sakura, Tochigi, Japan
🇯🇵
Niimi city Yukawa National health insurance clinic, Niimi, Okayama, Japan
🇯🇵
Konan Hospital, Oyama, Tochigi, Japan

and more 1 locations

A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People

Phase 3

Terminated

Conditions: Cardiovascular Events

Interventions: Drug: Aliskiren
Drug: Hydrochlorothiazide (HCTZ)
Drug: Placebo for Amlodipine
Drug: Placebo for Hydrochlorothiazide (HCTZ)
Drug: Placebo for Aliskiren
Drug: Amlodipine

First Posted Date: 2010-12-14

Last Posted Date: 2014-04-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 2336

Registration Number: NCT01259297

Locations: 🇸🇪
Novartis Investigative Site, Stockholm, Sweden

Assessment of Renin Inhibition on Insulin Sensitivity, Diastolic Function and Aortic Compliance

Not Applicable

Terminated

Conditions: Insulin Sensitivity
Aortic Compliance
Diastolic Function

Interventions: Drug: Valsartan and Aliskiren
Drug: Aliskiren
Drug: Amlodipine

First Posted Date: 2010-12-02

Last Posted Date: 2018-02-13

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 24

Registration Number: NCT01252238

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Clinical Pharmacology of Aliskiren in Combination With Cyclosporine in Cardiac Transplantation

Phase 4

Terminated

Conditions: Hypertension
Cardiac Transplantation

Interventions: Drug: Aliskiren

First Posted Date: 2010-11-07

Last Posted Date: 2018-06-29

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 1

Registration Number: NCT01235910

Locations: 🇺🇸
University of Colorado Denver, Aurora, Colorado, United States

Direct Renin Inhibition and the Kidney

Phase 1

Completed

Conditions: Renal Function

Interventions: Drug: VTP-27999
Drug: placebo
Drug: aliskiren

First Posted Date: 2010-10-08

Last Posted Date: 2016-02-29

Lead Sponsor: Vitae Pharmaceuticals, Inc.

Target Recruit Count: 22

Registration Number: NCT01217736

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA Nephropathy

Phase 4

Conditions: Glomerulonephritis, IGA
Hypertension

First Posted Date: 2010-08-19

Last Posted Date: 2011-06-27

Lead Sponsor: Kagawa University

Target Recruit Count: 30

Registration Number: NCT01184599

Locations: 🇯🇵
Department of Internal Medicine, Osaka City General Hospital, Osaka, Japan
🇯🇵
Kurume University, School of Medicine, Fukuoka, Japan
🇯🇵
Kinki University, Faculty of Medicine, Osaka, Japan

and more 1 locations

ALiskiren or Losartan Effects on bioMARKers of Myocardial Remodeling

Phase 4

Completed

Conditions: Hypertension
Left Ventricle Hypertrophy

Interventions: Drug: Aliskiren
Drug: Losartan
Drug: Amlodipine
Drug: Hydrochlorothiazide (HCTZ)

First Posted Date: 2010-08-05

Last Posted Date: 2014-07-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 74

Registration Number: NCT01176032

Locations: 🇪🇸
Novartis Investigative Site, Santander, Spain

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy